{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:02:05Z","timestamp":1791396125877,"version":"4.3.3"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.104941","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T08:08:04Z","timestamp":1692346084000},"page":"104941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Real world study of ocrelizumab in multiple sclerosis: Kuwait experience"],"prefix":"10.1016","volume":"79","author":[{"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"AlMojel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasem","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-9219","authenticated-orcid":false,"given":"Samar Farouk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104941_bib0001","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disabilitystatus scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104941_bib0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ana.410430409","article-title":"Multiple sclerosis: in situ evidence for antibody and complement-mediated demy- elination","volume":"43","author":"Storch","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104941_bib0003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/5532","article-title":"Identification of autoantibod- ies associated with myelin damage in multiple sclerosis","volume":"5","author":"Genain","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2023.104941_bib0004","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclero- sis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2023.104941_bib0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ana.20740","article-title":"Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients","volume":"59","author":"R\u00edo","year":"2006","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.104941_bib0006","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1474-4422(07)70196-5","article-title":"Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study","volume":"6","author":"Banwell","year":"2007","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104941_bib0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ncl.2011.01.004","article-title":"Pediatric multiple sclerosis","volume":"29","author":"Chitnis","year":"2011","journal-title":"Neurol. Clin."},{"issue":"2","key":"10.1016\/j.msard.2023.104941_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiplesclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104941_bib0009","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104941_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2011.08.001","article-title":"Disease activity free status in MS","volume":"1","author":"Lublin","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104941_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.msard.2023.104941_bib0012","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.104941_bib0013","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104941_bib0014","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proin- flammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.msard.2023.104941_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treat- ment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104941_bib0016","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104941_bib0017","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1352458516662728","article-title":"Data quality evaluation for observational multiple sclerosis registries","volume":"23","author":"Kalincik","year":"2017","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104941_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsingmultiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104941_bib0019","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104941_bib0020","series-title":"InPresented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, Oct 15","first-page":"EP1573","article-title":"Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the CLARITY and CLARITY extension studies","author":"Giovannoni","year":"2019"},{"key":"10.1016\/j.msard.2023.104941_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116973","article-title":"Real world application of ocrelizumab in multiple sclerosis: single-center experience of 128 patients","volume":"415","author":"Prockl","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104941_bib0022","first-page":"2020","article-title":"Real-world results of ocrelizumab treatment for primary progressive multiple sclerosis","author":"Daniels","year":"2020","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.msard.2023.104941_bib0023","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104941_bib0024","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: a multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3 Suppl","key":"10.1016\/j.msard.2023.104941_bib0025","first-page":"517","article-title":"Assessing the real-world effectiveness of ocrelizumab in patients withmultiple sclerosis- confidence one-year interim analysis [abstract]","volume":"26","author":"Buttmann","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104941_bib0026","series-title":"Common Terminology Criteria For Adverse Events v4.0","year":"2020"},{"key":"10.1016\/j.msard.2023.104941_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104941_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102725","article-title":"COVID-19 in ocrelizumab- treated people with multiple sclerosis","volume":"49","author":"Hughes","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.104941_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol. Open"},{"issue":"2","key":"10.1016\/j.msard.2023.104941_bib0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Fernandez-Diaz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2023.104941_bib0031","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple scle- rosis with suboptimal response to prior disease-modifying therapies: primary analysis from the phase 3b CASTING single-arm, open-label trial","author":"Vermersch","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104941_bib0032","article-title":"Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a sub- optimal response to previous disease-modifying therapy: a nonrandomized controlled trial","author":"Weinstock-Guttman","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104941_bib0033","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/0004-282x-anp-2020-0339","article-title":"Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America","volume":"79","author":"Rojas","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"issue":"2 Suppl","key":"10.1016\/j.msard.2023.104941_bib0035","first-page":"606","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 7.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis in the OPERA OLE [abstract no. P723]","volume":"27","author":"Giovannoni","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104941_bib0036","first-page":"101","article-title":"Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 8-year follow-up [abstract no. 158]","volume":"27","author":"Wolinksy","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2023.104941_bib0037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/21556660.2021.1989193","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in an Arab population","volume":"10","author":"Garcia-Ca\u00f1ibano","year":"2021","journal-title":"J. Drug Assess."},{"key":"10.1016\/j.msard.2023.104941_bib0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jocn.2022.02.033","article-title":"Farouk Ahmed S. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East","volume":"99","author":"Alroughani","year":"2022","journal-title":"J. Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.msard.2023.104941_bib0039","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/jcm11082081","article-title":"Prognostic markers of ocrelizumab effectiveness in multiple sclerosis: a real world observational multicenter study","volume":"11","author":"Lanzillo","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2023.104941_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104523","article-title":"Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: a single-center retrospective study","volume":"71","author":"Abuaf","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104941_bib0041","unstructured":"Ocrevus: EPAR-Product information. Available online at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf (accessed March 8, 2020)."},{"issue":"3","key":"10.1016\/j.msard.2023.104941_bib0042","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104941_bib0043","unstructured":"Worldometer real-time world statistics: Corona update live https:\/\/www.worldometers.info\/coronavirus\/; 2021 [accessed 03 March 2021]."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300442X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300442X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:02:50Z","timestamp":1727438570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482300442X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":42,"alternative-id":["S221103482300442X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104941","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world study of ocrelizumab in multiple sclerosis: Kuwait experience","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104941"}}